Latest News and Press Releases

Les fonds permettront d’avancer dans la découverte de traitements potentiellement disruptifs, à action rapide, pour la dépression résistante aux traitements et d'autres troubles...

Proceeds to advance potentially disruptive, fast-acting therapeutics for treatment-resistant depression and other neuropsychiatric disordersFirst-in-class, non-addictive, non-hallucinogenic molecules...

- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104...

New York, USA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight The depression treatment market is...

Pune, India, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The treatment-resistant depression treatment market size is projected to grow from USD 1.95 billion in 2023 to USD 4.06 billion by 2030, exhibiting a...

New York, USA, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Navitor, Supernus,...

Pune, India, Nov. 04, 2022 (GLOBE NEWSWIRE) -- The global treatment-resistant depression treatment market size was valued at USD 1.52 billion in 2021. The market is projected to grow from USD 1.55...

Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022        COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a...

Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK – 3 May 2022        COMPASS...

London, UK and New York, US, 19 January 2022  COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...